about
Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activationCalcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraineHistory of methysergide in migraineRole of opioid receptors in neurogenic dural vasodilation and sensitization of trigeminal neurones in anaesthetized ratsThe anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigsComparative effects of frovatriptan and sumatriptan on coronary and internal carotid vascular haemodynamics in conscious dogsOrofacial pain management: current perspectives.Pharmacological evidence for the 5-HT7 receptor mediating smooth muscle relaxation in canine cerebral arteriesPossible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370.Diencephalic and brainstem mechanisms in migraine.Neurogenic inflammation in the context of migraine.The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation.The discovery of a new drug class for the acute treatment of migraine.No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery.EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteriesSelective 5-HT1D alpha serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development.Sumatriptan: a selective 5-hydroxytryptamine receptor agonist for the acute treatment of migraine.Sumatriptan: efficacy and contribution to migraine mechanismsComparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors.5-HT1B-receptors and vascular reactivity in human isolated blood vessels: assessment of the potential craniovascular selectivity of sumatriptan.Effects of U46619 on contractions to 5-HT, sumatriptan and methysergide in canine coronary artery and saphenous vein in vitro.Sumatriptan-induced saphenous venoconstriction in the anaesthetized dog through 5-HT1-like receptor activationEffects of Voluntary Locomotion and Calcitonin Gene-Related Peptide on the Dynamics of Single Dural Vessels in Awake Mice.Comparison of the vasoconstrictor effects of the selective 5-HT1D-receptor agonist L-775,606 with the mixed 5-HT1B/1D-receptor agonist sumatriptan and 5-HT in human isolated coronary artery.Sumatriptan does not change calcitonin gene-related peptide in the cephalic and extracephalic circulation in healthy volunteersEffects of sumatriptan on the cerebral intraparenchymal microcirculation in the cat.Comparison of contractile responses to 5-hydroxytryptamine and sumatriptan in human isolated coronary artery: synergy with the thromboxane A2-receptor agonist, U466195-HT(1B) receptors inhibit glutamate release from primary afferent terminals in rat medullary dorsal horn neurons.Response properties of dural nociceptors in relation to headache.Experimental migraine models and their relevance in migraine therapy.Triptans in pregnancy.Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat--intravital microscope studies.The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache.Dopamine and migraine: biology and clinical implications.Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists.Migraine in the triptan era: progresses achieved, lessons learned and future developments.Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy.Chemical mediators of migraine: preclinical and clinical observations.Insights into the pharmacological targeting of the trigeminocervical complex in the context of treatments of migraine.Subcutaneous sumatriptan induces changes in frequency pattern in cluster headache patients.
P2860
Q24564969-C1CACED4-7536-40D3-AFB5-E0B59CA50DC7Q24632671-38D2155A-F4BB-4D4C-957F-56EC234E52AAQ28288040-AAE517E2-8DF0-41AB-A558-F3880BAA9C1DQ28343904-FF8695C4-34A2-4EFA-BE99-3971E3FF27BEQ28345449-71602D3C-D893-4401-B3B4-8FADE5C59C26Q28354207-D3C77794-51C1-41BD-BBAA-AB6403E51461Q30442178-D7D8C02A-FD1C-402F-B635-FB73F2DB7713Q33867649-54A96EC8-6327-414F-BB96-E97C26465861Q33889433-2CA07BA4-A367-448C-A446-1343972D9E7EQ34217686-5710323C-72FB-499E-8B6B-60DC9B0EE04BQ34218309-7911BDB4-BEF6-4DD4-A627-9DA0E5E2DCF8Q34373285-B70BEE5D-69B0-4195-9E1F-59531C547B9DQ34617817-08C7AC95-B415-43E5-B755-39D105038AA6Q35041894-4A38C62A-3800-49DD-A01F-72F0AB361D77Q35046135-D6286127-1BCF-43EE-BFE5-2961165602EEQ35189866-B7A125B0-D26C-430A-A801-9F6E892A16D4Q35229339-5EA9D948-B0CC-4AE0-8317-D74D01CB52B6Q35237666-39FE65C3-F233-4EE8-91E8-A54CC67047E3Q35802749-E7AC82B8-79DC-48EB-B04D-2ADBA61C2151Q35803690-734A51BA-A5BA-4C4E-B9A2-42D5574E7291Q35872811-D909FDE7-E7C1-4812-80C1-F8F13003AA4AQ35872845-ED2785C9-0081-4580-A8CB-D1043BBCD26DQ35934682-DFE2D7E0-2A17-423F-8BE9-E2792E928111Q36055018-65A3B219-3790-4E0F-A7BE-596E8A64DE6FQ36259595-ED461103-95E7-4A40-973D-576622563AEEQ36330113-5D6284B6-C441-45D7-8266-70AEBB10AE2AQ36330430-37BDD5AB-75BB-4A82-B659-6F9E789443AAQ36346921-E3EEB287-EC92-4B29-BE9D-AB372CF9DF43Q36403060-E3F1509A-2B27-4D04-8237-E4EFA73C093DQ36474260-B1A9DFD4-B190-4B13-B584-6636A4794CA7Q36817033-F970BDC9-652C-40A6-B679-42D055EBB744Q36869003-9E6F2AD2-6582-4C4E-B4A5-43507163FCEEQ36905403-537898CC-C8A5-48E9-8FEE-39E61D8BED65Q36986112-4897042E-5E1C-4B94-8378-CFFD43258D55Q37357042-2A926D5A-20BC-491C-95AC-09D38891B39DQ37558323-BE43E3C5-5771-4FFA-B72F-C935BD7824D6Q37818258-10902ADD-AA1E-4DCB-A858-1038F1E58ACCQ37883455-37CBB75D-D1C3-4ECC-9B7A-1D1262F838E8Q38129436-F394D519-7907-4870-BF88-1EC61926254CQ39379377-8196E6F0-B139-40EB-8179-18A6D1A4B21F
P2860
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh
1991年學術文章
@zh-hant
name
Mode of action of the anti-migraine drug sumatriptan.
@ast
Mode of action of the anti-migraine drug sumatriptan.
@en
type
label
Mode of action of the anti-migraine drug sumatriptan.
@ast
Mode of action of the anti-migraine drug sumatriptan.
@en
prefLabel
Mode of action of the anti-migraine drug sumatriptan.
@ast
Mode of action of the anti-migraine drug sumatriptan.
@en
P1476
Mode of action of the anti-migraine drug sumatriptan.
@en
P2093
P304
P356
10.1016/0165-6147(91)90630-B
P577
1991-12-01T00:00:00Z